Sign in or Register
  • Home
    • The story of Aurigene
    • The Aurigene approach
    • Our impact
    • Media center
    • Our publications
  • About Us
    • Our journey
    • Our purpose
    • Our Core Values
    • Our milestones
    • Management Team
    • Board of Directors
    • Scientific Advisors
  • Science
    • Science
      • Our research
      • Our platform technologies
      • Our publications
    • Pipeline
      • Proprietary Pipeline
      • Clinical Candidates from Partnered Programs
  • News and Events
    • Newsroom
    • Events
  • Careers
    • Life at Aurigene
    • Working at Aurigene
    • Perks at Aurigene
    • Teamwork
    • Current Openings
    • A word from Aurigeneans
  • Contact Us
Aurigene
Home
  • Home
    • The story of Aurigene
    • The Aurigene approach
    • Our impact
    • Media center
    • Our publications
  • About Us
    • Our journey
    • Our purpose
    • Our Core Values
    • Our milestones
    • Management Team
    • Board of Directors
    • Scientific Advisors
  • Science
    • Science
      • Our research
      • Our platform technologies
      • Our publications
    • Pipeline
      • Proprietary Pipeline
      • Clinical Candidates from Partnered Programs
  • News and Events
    • Newsroom
    • Events
  • Careers
    • Life at Aurigene
    • Working at Aurigene
    • Perks at Aurigene
    • Teamwork
    • Current Openings
    • A word from Aurigeneans
  • Contact Us
  1. Home
  2. Publication
  3. Page 5
May 2, 2023
by admin aurigene

Amino Acid inspired oral immune checkpoint antagonists for cancer therapy

May 1, 2023
by admin aurigene

Oral Immune Checkpoint Antagonist Dually Targeting TIGIT & PD-1 Pathways for Cancer Therapy

May 1, 2023
by admin aurigene

Characterization of the anti-tumor immune activation potential of AUR107, a novel small molecule p300/CBP bromodomain inhibitor

May 1, 2023
by admin aurigene

Orally Bioavailable CBP and p300 Selective Degraders for the Treatment of AR- and ER- dependent Cancers

April 28, 2023
by admin aurigene

The impact of structure-guided drug design on clinical agents

April 28, 2023
by admin aurigene

The multiple orthogonal tools approach to define molecular causation in the validation of druggable targets

April 28, 2023
by admin aurigene

Rational selection of structurally diverse natural product scaffolds with favorable ADME properties for drug discovery

April 28, 2023
by admin aurigene

Development of DPP IV Inhibitors

April 28, 2023
by admin aurigene

A Structure-Based Strategy for New Drug Discovery

April 28, 2023
by admin aurigene

Peptide Architecture: Adding an α-Helix to PYY lysine side chain provides nanomolar binding and body weight lowering effects

1... 34567... 18
Home
  • Pipeline
  • Publications
  • Science
  • News and Events
  • Careers
Careers
Contact Us
Linkedin X-twitter

Governance

Code of Business Conduct
and Ethics

  • Statement of Policy
  • Link to Raise Concerns

Annual Reports

  • Link to View Report

Safety, Health, Environment
and Sustainability

  • Policy Statement and Reports

Information Security
Management System

  • ISO/IEC 27001:2022 Certificate

Policies

CSR

  • Commitee
  • Statement of Policy
  • Guiding Principles
  • Activities

Remuneration Policy

  • Statement of Policy

© 2022 Aurigene Discovery Technologies

Privacy & GDPR policy

Cookie policy

Crafted by: Pink Lemonade Communications Pvt. Ltd.

© 2022 Aurigene Oncology

Privacy and GDPR Policy

Cookie Policy

Apply Now